Fenofibrate NDC 42291-427

NDC codes

FDA NDC Directory

Product NDC (as listed)42291-427Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42291-0427Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42291-427-50	42291042750	500 TABLET, FILM COATED in 1 BOTTLE (42291-427-50)Marketed from Mar 8, 2023
42291-427-90	42291042790	90 TABLET, FILM COATED in 1 BOTTLE (42291-427-90)Marketed from Mar 8, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibrate
Generic name (nonproprietary): fenofibrate
Active ingredients: Fenofibrate — 160 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: AvKARE
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207803
Marketing start: Mar 8, 2023
Listing expires: Dec 31, 2027
Identifiers: Product ID 42291-427_485d31e4-a2a8-8165-e063-6294a90a14fcSPL ID 485d31e4-a2a8-8165-e063-6294a90a14fcSPL set ID f669f231-98b9-5014-e053-2a95a90a4e4cRxCUI 349287UNII U202363UOS
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442291042750 followed by a unit qualifier and the quantity

Package 42291-0427-50. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 14, 2026.

Indications (excerpt from the label)

Fenofibrate tablets are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total choles…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207803

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207803
Product	Strength	Form · route	Labeler	Product NDC
Fenofibrate	Fenofibrate 160 mg/1	Tablet, Film coatedOral	Westminster Pharmaceuticals, LLC	69367-254
Fenofibrate	Fenofibrate 160 mg/1	Tablet, Film coatedOral	Proficient Rx LP	71205-949
Fenofibrate	Fenofibrate 54 mg/1	Tablet, Film coatedOral	Bostal LLC	35561-343
Fenofibrate	Fenofibrate 160 mg/1	Tablet, Film coatedOral	Bostal LLC	35561-344